Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
Keywords: COVID-19; baricitinib; hyper-inflammation.
All Keywords
【저자키워드】 COVID-19, Baricitinib, hyper-inflammation, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Baricitinib, Hydroxychloroquine, clinical trials, Randomized, hyperinflammation, hyper-inflammation, moderate, patients, retrospective, treatment of COVID-19, increased mortality, patient cohort, investigated, 【제목키워드】 Baricitinib,
【저자키워드】 COVID-19, Baricitinib, hyper-inflammation, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Baricitinib, Hydroxychloroquine, clinical trials, Randomized, hyperinflammation, hyper-inflammation, moderate, patients, retrospective, treatment of COVID-19, increased mortality, patient cohort, investigated, 【제목키워드】 Baricitinib,
{{{ 추상적인 }}}
과염증은 2019년 코로나바이러스 질병(COVID-19)의 사망률 증가와 관련이 있습니다. 이 후향적 통제되지 않은 중등도 COVID-19 환자 코호트에서 바리시티닙과 하이드록시클로로퀸을 병용한 치료는 15명의 환자 중 11명의 회복과 관련이 있었습니다. COVID-19 치료를 위한 바리시티닙은 무작위 대조 임상 시험에서 추가로 조사되어야 합니다.
{{ 키워드: }} 코로나19; 바리시티닙; 과염증.